Skip to main
DRTS

DRTS Stock Forecast & Price Target

DRTS Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Tau Medical Ltd has achieved a significant operational milestone by securing a radioactive material license from the New Hampshire Bureau of Public Health Protection, allowing for the upcoming commencement of U.S. manufacturing of its proprietary Alpha DaRT technology, anticipated to start in 2026. The company has maintained a strong cash position which is critical for its continued development and commercialization efforts in the oncology sector. Despite a net loss of $11.7 million for the period, slightly exceeding prior estimates, the potential of Alpha DaRT to address unmet needs in cancer treatment and its solidifying infrastructure point to a positive long-term outlook for the company's stock.

Bears say

Alpha Tau Medical reported a net loss of $11.7 million in the third quarter of 2025, highlighting ongoing financial challenges as the company navigates critical stages of development for its Alpha DaRT technology. The company faces significant risks, including the potential failure of clinical trials, obstacles in securing regulatory approval in the U.S., and challenges related to achieving commercial success in a competitive market. Additionally, the threat of potential dilution further complicates the investment outlook, raising concerns over the company's ability to stabilize and grow its financial position in the near term.

DRTS has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Tau Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Tau Medical (DRTS) Forecast

Analysts have given DRTS a Strong Buy based on their latest research and market trends.

According to 2 analysts, DRTS has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Tau Medical (DRTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.